Panacea Index Logo

Command Palette

Search for a command to run...

Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.

Clinical and experimental nephrology
December 1, 2018
Lyudmila Milovanova et al. (11 authors)
Comparative StudyJournal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to compare the effects of a low-protein diet (LPD) with and without essential amino acid ketoanalogue supplementation (KA) on serum Klotho, FGF-23 levels, and cardiovascular parameters in CKD patients.

Results Summary

The LPD + KA group showed improved FGF-23 and Klotho levels, reduced cardiovascular calcification, and better nutritional status compared to LPD alone, which was associated with increased malnutrition risk and adverse cardiovascular changes.

Population

Non-diabetic CKD patients (stages 3b-4), compliant with LPD (0.6 g/kg/day).

Effective Dosage

0.6 g/kg of body weight/day (LPD).

Duration

14 months.

Interactions

None mentioned.

Extracted Claims (8)
InterventionDirectionEndpointPopulationDosageImpactClaim #
low protein diet (LPD) alone
decrease
body mass indices
non-diabetic CKD 3b-4 stage patients
p=0.046
decrease
#1
low protein diet (LPD) alone
decrease
muscle body mass
men
p=0.027
decrease
#2
low protein diet (LPD) alone
decrease
muscle body mass
woman
p=0.044
decrease
#3
low protein diet (LPD) with essential amino acid ketoanalogue supplementation (KA)
decrease
FGF-23
non-diabetic CKD 3b-4 stage patients
p=0.029
lower
#4
low protein diet (LPD) with essential amino acid ketoanalogue supplementation (KA)
increase
sKlotho
non-diabetic CKD 3b-4 stage patients
p=0.037
higher
#5
low protein diet (LPD) alone
increase
AI (stiffness (augmentation) indices)
non-diabetic CKD 3b-4 stage patients
p=0.034
increase
#6
low protein diet (LPD) alone
increase
VCS (valvular calcification score)
non-diabetic CKD 3b-4 stage patients
p=0.048
increase
#7
low protein diet (LPD) alone
increase
LVMMI
non-diabetic CKD 3b-4 stage patients
p=0.023
increase
#8
Abstract

BACKGROUND: A low protein diet (LPD) with essential amino acid ketoanalogue supplementation (KA) may contribute in improving of chronic kidney disease (CKD), while the exact mechanisms of KA's effect are not established yet. We have conducted a prospective, randomized, controlled comparative study of LPD + KA and LPD alone in relation to serum Klotho, FGF-23 levels in CKD patients. METHODS: 79 non-diabetic CKD 3b-4 stage patients, compliant with LPD diet (0.6 g/kg of body weight/day), had been selected. The patients were randomized into two groups. The first group (42 patients) received LPD + КA. The second group (37 patients) continued the LРD alone. In addition to routine tests, serum Klotho, FGF-23 levels, as well as bioimpedance analysis, sphygmography (stiffness (augmentation) indices (AI), central (aortal) blood pressure) with a «SphygmaCor» device; echocardiography (valvular calcification score (VCS) and LVMMI), were performed. RESULTS: There were body mass indices' decrease (p = 0.046), including muscle body mass in men (p = 0.027) and woman (p = 0.044) in the LPD group to the end of study (14th month). In addition, lower FGF-23 (p = 0.029), and higher sKlotho (p = 0.037) were detected in the LPD + KA group compared to the LPD one. The increase in AI (p = 0.034), VCS (p = 0.048), and LVMMI (p = 0.023) was detected more often in the LPD group at the end of study. CONCLUSION: LPD + KA provides support for nutrition status and contributes to more efficient correction of FGF-23 and Klotho abnormalities that may result in cardiovascular calcification and cardiac remodeling decreasing in CKD. At the same time, a prolonged LPD alone may lead to malnutrition.

Medical Subject Headings (MeSH)
Amino Acids, EssentialDiet, Protein-RestrictedFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseHumansHypertrophy, Left VentricularKlotho ProteinsMaleMalnutritionPilot ProjectsProspective StudiesRenal Insufficiency, ChronicVascular Calcification
Study Links
Quality Scores
Safety70
Efficacy85/10
Quality80/10
Citation Metrics
Total Citations28
Citations/Year4.0
Relative Citation Ratio1.56
NIH Percentile66.4%
Research Impact Scores
APT Score0.75
Weight Score2.18
Normalized Score0.78
Related Supplements